Vol 94, No 5 (2023)
Research paper
Published online: 2022-08-24

open access

Page views 2003
Article views/downloads 764
Get Citation

Connect on Social Media

Connect on Social Media

Evaluation of the effect of multi-dose methotrexate therapy on ovarian reserve in ectopic pregnancies: is polycystic ovarian morphology a protective condition for ovarian reserve?

Furkan Çetin1, Neslihan Bayramoglu Tepe2, Ali Irfan Kutlar2
Pubmed: 36106469
Ginekol Pol 2023;94(5):407-414.

Abstract

Objectives: The study aims to evaluate the effects of multi-dose methotrexate (MTX) or subsequent salpingectomy on ovarian reserve and explain the conditions that cause the change in serum anti-müllerian hormone (AMH) levels.
Material and methods: Our department had 58 tubal ectopic pregnancy (EP) patients treated with a multiple-dose MTX protocol or subsequent salpingectomy between 2017–2020. Serum AMH level was measured in each patient before the medication and 3–6 months after therapy. Patients’ details were recorded and analyzed later.
Results: The mean AMH value decreased in 32 patients (−17.8%), increased in 26 patients (+31.5%) (p < 0.0001). In the group with an increase, there was a significantly high number of patients with a polycystic ovary (PCO) condition compared to the other group (p = 0.0001). The post-treatment serum AMH levels increased in patients with PCO, whereas those decreased in patients without PCO (p < 0.001).
Conclusions: Multiple-dose MTX or subsequent salpingectomy treatment in tubal ectopic pregnancy (EP) patients might not refer to significant differences in patients’ AMH levels. Remarkably, post-treatment AMH levels were significantly increased in EP patients with PCO and decreased in those without this condition. PCO may be a protective condition for ovarian reserve.

Article available in PDF format

View PDF Download PDF file

References

  1. Oriol B, Barrio A, Pacheco A, et al. Systemic methotrexate to treat ectopic pregnancy does not affect ovarian reserve. Fertil Steril. 2008; 90(5): 1579–1582.
  2. Barnhart K, Hummel AC, Sammel MD, et al. Use of “2-dose” regimen of methotrexate to treat ectopic pregnancy. Fertil Steril. 2007; 87(2): 250–256.
  3. Bachman EA, Barnhart K. Medical management of ectopic pregnancy: a comparison of regimens. Clin Obstet Gynecol. 2012; 55(2): 440–447.
  4. Cheng X, Tian X, Yan Z, et al. Comparison of the fertility outcome of salpingotomy and salpingectomy in women with tubal pregnancy: a systematic review and meta-analysis. PLoS One. 2016; 11(3): e0152343.
  5. Chang HJ, Han SH, Lee JR, et al. Impact of laparoscopic cystectomy on ovarian reserve: serial changes of serum anti-Müllerian hormone levels. Fertil Steril. 2010; 94(1): 343–349.
  6. Broekmans FJ, Kwee J, Hendriks DJ, et al. A systematic review of tests predicting ovarian reserve and IVF outcome. Hum Reprod Update. 2006; 12(6): 685–718.
  7. Feyereisen E, Méndez Lozano DH, Taieb J, et al. Anti-Müllerian hormone: clinical insights into a promising biomarker of ovarian follicular status. Reprod Biomed Online. 2006; 12(6): 695–703.
  8. Kissell KA, Danaher MR, Schisterman EF, et al. Biological variability in serum anti-Müllerian hormone throughout the menstrual cycle in ovulatory and sporadic anovulatory cycles in eumenorrheic women. Hum Reprod. 2014; 29(8): 1764–1772.
  9. Homburg R, Ray A, Bhide P, et al. The relationship of serum anti-Mullerian hormone with polycystic ovarian morphology and polycystic ovary syndrome: a prospective cohort study. Hum Reprod. 2013; 28(4): 1077–1083.
  10. March WA, Moore VM, Willson KJ, et al. The prevalence of polycystic ovary syndrome in a community sample assessed under contrasting diagnostic criteria. Hum Reprod. 2010; 25(2): 544–551.
  11. Guo Y, Liu S, Hu S, et al. High serum anti-Müllerian hormone concentrations are associated with poor pregnancy outcome in fresh IVF/ICSI cycle but not cumulative live birth rate in PCOS patients. Front Endocrinol (Lausanne). 2021; 12: 673284.
  12. Tal R, Seifer CM, Khanimov M, et al. High serum Antimullerian hormone levels are associated with lower live birth rates in women with polycystic ovarian syndrome undergoing assisted reproductive technology. Reprod Biol Endocrinol. 2020; 18(1): 20.
  13. Rotterdam ESHRE/ASRM-Sponsored PCOS Consensus Workshop Group. Revised 2003 consensus on diagnostic criteria and long-term health risks related to polycystic ovary syndrome. Fertil Steril. 2004; 81(1): 19–25.
  14. Wang J, Wei Y, Diao F, et al. The association between polycystic ovary syndrome and ectopic pregnancy after in vitro fertilization and embryo transfer. Am J Obstet Gynecol. 2013; 209(2): 139.e1–139.e9.
  15. Ozel S, Alkan M, Tokmak A, et al. Relationship between polycystic ovarian morphology and ectopic pregnancy. J Reprod Infertil. 2021; 22(1): 32–37.
  16. Boots CE, Gustofson RL, Feinberg EC. Does methotrexate administration for ectopic pregnancy after in vitro fertilization impact ovarian reserve or ovarian responsiveness? Fertil Steril. 2013; 100(6): 1590–1593.
  17. Uyar I, Yucel OU, Gezer C, et al. Effect of single-dose methotrexate on ovarian reserve in women with ectopic pregnancy. Fertil Steril. 2013; 100(5): 1310–1313.
  18. Shirazi M, Pooransari P, Hajiha N, et al. Effect of single-dose methotrexate treatment on ovarian reserve in women with ectopic pregnancy undergoing infertility treatment: a single-center experience. Int J Fertil Steril. 2020; 14(1): 23–26.
  19. Ulug P, Oner G. Evaluation of the effects of single or multiple dose methotrexate administration, salpingectomy on ovarian reserve of rat with the measurement of anti-Müllerian hormone (AMH) levels and histological analysis. Eur J Obstet Gynecol Reprod Biol. 2014; 181: 205–209.
  20. Sahin Ersoy G, Turhan OT, Sakin O, et al. Comparison of the long-term effects of single-dose methotrexate and salpingectomy on ovarian reserve in terms of anti-müllerian hormone levels. Hum Fertil (Camb). 2016; 19(4): 262–267.
  21. Benian A, Guralp O, Uzun DD, et al. The effect of repeated administration of methotrexate (MTX) on rat ovary: measurement of serum antimullerian hormone (AMH) levels. Gynecol Endocrinol. 2013; 29(3): 226–229.
  22. Sahin C, Taylan E, Akdemir A, et al. The impact of salpingectomy and single-dose systemic methotrexate treatments on ovarian reserve in ectopic pregnancy. Eur J Obstet Gynecol Reprod Biol. 2016; 205: 150–152.
  23. Hannoodee M, Mittal M. Methotrexate. StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing. 2022–Available from: https://www.ncbi.nlm.nih.gov/books/NBK556114.
  24. Cobellis G, Pierno G, Pecori E, et al. Methotrexate treatment for tubal pregnancy. Criteria for medical approach. Minerva Ginecol. 2003; 55(6): 531–535.
  25. Taran FA, Kagan KO, Hübner M, et al. The diagnosis and treatment of ectopic pregnancy. Dtsch Arztebl Int. 2015; 112(41): 693–703; quiz 704.
  26. La Marca A, Giulini S, Orvieto R, et al. Anti-Müllerian hormone concentrations in maternal serum during pregnancy. Hum Reprod. 2005; 20(6): 1569–1572.
  27. van Disseldorp J, Lambalk CB, Kwee J, et al. Comparison of inter- and intra-cycle variability of anti-Mullerian hormone and antral follicle counts. Hum Reprod. 2010; 25(1): 221–227.
  28. Gracia CR, Sammel MD, Freeman E, et al. Impact of cancer therapies on ovarian reserve. Fertil Steril. 2012; 97(1): 134–40.e1.
  29. Lantinga GM, Simons AHM, Kamps WA, et al. Imminent ovarian failure in childhood cancer survivors. Eur J Cancer. 2006; 42(10): 1415–1420.
  30. Sezik M, Ozkaya O, Demir F, et al. Total salpingectomy during abdominal hysterectomy: effects on ovarian reserve and ovarian stromal blood flow. J Obstet Gynaecol Res. 2007; 33(6): 863–869.
  31. Chan CCW, Ng EHY, Li CF, et al. Impaired ovarian blood flow and reduced antral follicle count following laparoscopic salpingectomy for ectopic pregnancy. Hum Reprod. 2003; 18(10): 2175–2180.
  32. Yang C, Cai J, Geng Y, et al. Multiple-dose and double-dose versus single-dose administration of methotrexate for the treatment of ectopic pregnancy: a systematic review and meta-analysis. Reprod Biomed Online. 2017; 34(4): 383–391.
  33. La Marca A, Grisendi V, Griesinger G. How much does AMH really vary in normal women? Int J Endocrinol. 2013; 2013: 959487.
  34. Köninger A, Kauth A, Schmidt B, et al. Anti-Mullerian-hormone levels during pregnancy and postpartum. Reprod Biol Endocrinol. 2013; 11: 60.
  35. Nelson SM, Stewart F, Fleming R, et al. Longitudinal assessment of antimüllerian hormone during pregnancy-relationship with maternal adiposity, insulin, and adiponectin. Fertil Steril. 2010; 93(4): 1356–1358.
  36. Dewailly D, Andersen CY, Balen A, et al. The physiology and clinical utility of anti-Mullerian hormone in women. Hum Reprod Update. 2014; 20(3): 370–385.
  37. Pigny P, Merlen E, Robert Y, et al. Elevated serum level of anti-mullerian hormone in patients with polycystic ovary syndrome: relationship to the ovarian follicle excess and to the follicular arrest. J Clin Endocrinol Metab. 2003; 88(12): 5957–5962.